Dr Javed Butler: Vericiguat & Hypotension

Dr. Javed Butler addresses concerns about hypotension when prescribing vericiguat for heart failure patients. He emphasizes balancing potential side effects with the benefits of treatment, noting that vericiguat demonstrated good tolerability in the Victoria trial. Dr. Butler provides practical strategies to minimize hypotension risk, including staggering medication schedules, reducing diuretic doses, and addressing volume depletion. He highlights that initiating vericiguat, even at lower doses, offers significant benefits compared to withholding therapy. While the target dose of 10 mg is ideal, he advises clinicians to tailor treatment to patient tolerability, ensuring effective management without compromising safety.